key: cord-0800312-jeimv4qo
authors: Visco, Carlo; Marcheselli, Luigi; Mina, Roberto; Sassone, Marianna; Guidetti, Anna; Penna, Domenico; Cattaneo, Chiara; Bonuomo, Valentina; Busca, Alessandro; Ferreri, Andrés José María; Bruna, Riccardo; Petrucci, Luigi; Cairoli, Roberto; Salvini, Marco; Bertù, Lorenza; Ladetto, Marco; Pilerci, Sofia; Pinto, Antonello; Ramadan, Safaa; Marchesi, Francesco; Cavo, Michele; Arcaini, Luca; Coviello, Elisa; Romano, Alessandra; Musto, Pellegrino; Massaia, Massimo; Fracchiolla, Nicola; Marchetti, Monia; Scattolin, Annamaria; Tisi, Maria Chiara; Cuneo, Antonio; Porta, Matteo Della; Trentin, Livio; Turrini, Marco; Gherlinzoni, Filippo; Tafuri, Agostino; Galimberti, Sara; Bocchia, Monica; Cardinali, Valeria; Cilloni, Daniela; Corso, Alessandro; Armiento, Daniele; Luigi, Rigacci; Barbera, Elettra Ortu La; Gambacorti-Passerini, Carlo; Visani, Giuseppe; Vallisa, Daniele; Venditti, Adriano; Selleri, Carmine; Conconi, Annarita; Tosi, Patrizia; Lanza, Francesco; Candoni, Anna; Krampera, Mauro; Corradini, Paolo; Passamonti, Francesco; Merli, Francesco
title: A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
date: 2021-10-15
journal: Blood Adv
DOI: 10.1182/bloodadvances.2021005691
sha: 4f66a49a3deb6d37250f66c5bb124220ddc3250c
doc_id: 800312
cord_uid: jeimv4qo

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behaviour and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not admitted cohort, n=388), or required hospitalization (n=468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95%CI 11-15%) and 23% (95%CI 20-27%), respectively. Anti-lymphoma treatment, including anti-CD20 containing regimens, did not impact on survival. Patients with Hodgkin's lymphoma had the more favourable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment for their underlying disease, and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

and 23% (95%CI 20-27%) at 30-and 100 days, respectively -An easy-to-use prognostic model stratifies patients with lymphoma and COVID-19 into 3 groups with extremely different survival expectations

Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behaviour and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not admitted cohort, n=388), or required hospitalization (n=468), and median age was 63 years (range . Overall, the 30-and 100-days mortality was 13% (95%CI 11-15%) and 23% (95%CI 20-27%), respectively. Anti-lymphoma treatment, including anti-CD20 containing regimens, did not impact on survival. Patients with Hodgkin's lymphoma had the more favourable survival, but this was partly related to significantly younger age.

The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate and highrisk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment for their underlying disease, and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.

Since its first detection in Wuhan, China, in December, 2019 1 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 130 million people worldwide, with deaths that are approximating 3 millions people. Italy was the first European country where the virus was isolated on the 31st of January, 2020, from two Chinese tourists in Rome 2 . Since then, in a little more than one year, more than 3.5 million cases have been registered in the country.

The clinical spectrum of individuals who are infected with SARS-CoV2 is largely heterogeneous, ranging from mild flu-like symptoms to life-threatening respiratory failure 3 .

The leading cause of mortality is the acute respiratory distress syndrome, due to the release of proinflammatory mediators, intense immune response and endothelial damage [4] [5] [6] . Notwithstanding, comorbidities have been shown to affect disease severity and patient outcomes 7, 8 . Mortality due to the infection is largely dependent on patients age, with a log-linear increase by age among individuals older than 30 years, with peaks exceeding 8% in older than 80 9 . Furthermore, subgroups of patients with COronaVIrus Disease 19 (COVID19) have been identified to be at increased risk of morbidity and mortality, including male gender, hypertension, chronic lung disease, diabetes, immunodeficiency and cancer 10 . Patients with solid cancer or with hematological malignancies (HM) often follow a more severe and rapid disease course, with requirement of high-levels intensive care and an increased risk of COVID19-related death [11] [12] [13] [14] [15] , as compared to the general population 12 .

Lymphomas are a heterogeneous group of cancer, carrying multiple immune dysfunctions of the innate and adaptive immune system, including frequent low immunoglobulin serum levels. Crippled cellular and humoral immunity places these patients at risk of a diverse array of infections including COVID19 16 . Patients with lymphoma have been underrepresented in most cancer or HM series, with just few recent reports addressing specifically their behaviour, in relatively small cohorts 17, 18 . These reports were retrospective, mostly relied on hospitalized patients, and focused on the first wave of infection (spring, 2020).

With this study, the Italian Hematology Alliance on COVID19 (ITA-HEMA-COV) and the Fondazione Italiana Linfomi (FIL) collected and analysed data from adult patients with lymphoma and COVID19 infection, requiring hospitalisation or not, for COVID19. We report results from a cohort study reporting data of 64 hospitals in Italy, with the aim of improving assistance and prognostication of the disease in such a frail cohort of the entire population affected by COVID19.

This multicentre, non-interventional study included a retrospective data review (partly reported in Passamonti et al 11 ) , and a prospective cohort study, which was implemented in the same centers since the 23rd of june, 2020. between Jun 23, 2020 and Feb 1, 2021 (prospective cohort), with data cutoff on April 1, 2021, were included in this analysis. Inclusion criteria were a diagnosis of lymphoma according to WHO-criteria and laboratory-confirmed SARS-CoV-2 infection, tested by RT-PCR on nasopharyngeal swabs following standardized national recommendations 11 . The trial was approved by the institutional review board of each haematology unit. Written informed consent was collected from all patients.

Data on patient characteristics and outcomes were extracted by study investigators from data collection electronic forms obtained from local medical records, and queries were performed to enrich the data on lymphoma patients. Diagnosis of lymphoma subtype was made on the basis of the most recent WHO classification of haematopoietic tumours 19 .

The histological diagnosis of the lymphoproliferative disorder and stage at diagnosis, the therapeutic history of each patient with number of previous lines of therapy, best response to therapy, disease status at COVID diagnosis, and demographic features at the time of enrollment including age, sex, Charlson Comorbidity Index, biochemical parameters (haemoglobin, haematocrit, platelets, leucocytes, lymphocytes, clotting tests, serum lactate dehydrogenase, and C-reactive protein), time since diagnosis of lymphoma to COVID19 diagnosis, time from last lymphoma therapy to COVID19 diagnosis, and COVID19 severity including admission to the intensive care unit (ICU) were recorded.

Definitions of active disease status (progressive disease or partial remission), active therapy (delivered within the previous 6 months), severity of COVID19 as mild, severe, or critical, were previously described 11 . This study was registered with ClinicalTrials.gov, NCT04352556.

Characteristics of the study population were described for admitted and non-admitted Figure 1S . All statistical analysis was done with Stata 17SE and all statistical tests were two-sided.

Patients were grouped into the following histologic categories: (1) large B-cell lymphomas As for therapeutic schemes, we identified the following categories: (1) chemotherapy alone, (2) radiotherapy alone, (3) immunotherapy, (4) immunochemotherapy, (5) biologics (single agents or in combination) and (6) containing or not.

The complete cases cohort was utilized to develop and select the model by means of the likelihood-ratio test. The importance of covariates was evaluated after 1000 bootstrap resamples of the selection model, based on minimum AIC (Akaike's information criterion).

The proportionality of risk of the multivariable Cox PH model was checked graphically by means of the scaled Schoenfeld residuals 22 . Finally, the model was internally validated using bootstrap techniques to evaluate the discriminant power (C-index, which measures the probability that given a pair of randomly selected patients, the model will correctly predict which patient will experience failure first), shrinkage factor (check for overfitting: the statistical model fitted the noise in the data rather than the relation between covariates and outcome, with loss of generalizability) 14 months, platelets (PLT) <100 vs ≥100 10 -9 /L and ALC <650 vs ≥650 10 -9 /L (the cut-point for ALC is described in Supplementary Figure 1S ). We assigned a weight to each variable according to its relative importance, derived from the ratio of z-Wald values found in the Cox PH model. The ratio between the z-score for any factor was divided by minimum zscore observed (considered as reference) and the weights were obtained rounding the ratio. Thus, the score was the sum of weights. Finally, from the analysis of the Kaplan-Meier curves, the prognostic score was grouped into three risk levels (low, intermediate, and high).

The study included 856 patients, of whom 237 were included in the previous analysis 11 , and 619 were enrolled prospectively since the closure of the initial database. The clinical and laboratory characteristics, lymphoma histologies, of the whole series, then divided between hospitalized patients and those who were not initially admitted to the hospital are reported in Table 1 . Overall, median age was 63 (range 19-94), and 504 (59%) were males. As expected, patients necessitating hospitalization since the initial positive swab, the so-called admitted cohort (n=468), were in worse clinical conditions than those followed-up as outpatients (n=388), with 59% and 8% with severe or critical disease, respectively. Therefore, as shown in Table 1 , the clinical and laboratory features of the two cohorts were significantly different. Not admitted patients were younger, were more likely to be females, had an inferior comorbidity score, and higher hemoglobin level and ALC.

Admitted patients instead were more likely to have a recent lymphoma diagnosis, and an active disease, while no difference was observed regarding number of previous antilymphoma therapy lines. A logistic regression calculation describing the probability of hospital admission according to different characteristics of patients is shown in supplementary Table 1S . The distribution of lymphoma histotypes was in line with the expected prevalence of these diseases in the adult unselected population. Interestingly, patients affected by cHL were more likely to be followed in the outpatient setting.

Overall, 165 patients died after a median follow-up of 66 days (range 1-395), with a CFR of 19.5%, and an incidence of 2.45x1000 person-days. Overall, the 30-and 100-days mortality was 13% (95%CI 11-15%) and 23% (95%CI 20-27%), respectively, as shown in Figure 1A . The vast majority of deaths were due to COVID19 infection or complications related to the infection (91%, versus 15 unrelated, 9%). Unrelated deaths were due to lymphoma progression in 13 of the 15 cases. As expected, patients admitted to the hospital had significantly worse OS than patients not admitted (p<0.0001), as shown in Figure 1B . The CFR of admitted versus not admitted patients was 33.4% and 3.8%, respectively. The mortality incidence of admitted and not admitted patients was 4.03 and 0.50x1000 person-days, respectively. The 30-days mortality for mild, severe and critical COVID19 infection, which is a parameter strictly related to hospitalization, were 4% (95CI 3-7%), 22% (95CI 17-28%) and 45% (95CI 33-57%), respectively. The 100-days rates were 9% (95CI 6-13%), 38% (95CI 31-46%) and 75% (95CI 61-87%) for mild, severe and critical group, respectively, as shown in Table2. The OS for status of COVID19 showed the same pattern in prospective or retrospective cohort (test for trend, p<0.001 for both).

Factors that were associated with significantly impaired OS in univariate analysis are shown in Table 2 .

No difference in OS was observed between the prospective and retrospective cohorts (3months OS 76% vs 75% respectively, p=0.205). Possibly due to selection bias, the retrospective series had higher rate of hospitalization and lower rate of mild-COVID compared to the prospective series (74% vs 44%, p<0.001; 54% vs 68%, p=0.001, respectively Figure 2S ). Nevertheless, bendamustine mortality curve raised sharply in the initial 50-days from COVID19 infection, suggesting that a detrimental effect of the drug cannot be excluded in our relatively small sample. When comparing patients that had received anti-CD20 immunotherapy (n=163), with patients treated without these drugs, no difference was observed in terms of OS (p=0.65, Figure 2S ), with mortality rates that were quite superimposable in the initial 100 days from infection. The absence of a detrimental acute impact of anti-CD20 on mortality was confirmed in the 16 FL patients that underwent or were undergoing maintenance therapy with anti-CD20 in our series (data not shown). Of lymphoma histologies, cHL was associated with significantly better OS than others (p=0.001), while low-grade lymphomas, including both FL and i-NHL, were borderline (p=0.049, Figure 1C ). Indeed, when we considered the impact of age, gender and the frequency of admission to the hospital of patients with cHL, which was different from other histologies, as expected, this advantage was weakened (log rank test stratified by age>65, gender and hospital admission, p=0.318).

Interestingly, the time interval between lymphoma diagnosis and COVID19 infection was inversely related to mortality, with 36 months as cut-off, meaning that the longer the interval the inferior the probability of death. As shown in Figure 3 , the risk of death declined over time in a linear fashion as we moved away from the time of lymphoma diagnosis.

The model was built from 429 patients with complete data, where multivariable analysis revealed that age >65 years-old, male gender, absolute lymphocyte count less than 650 x 10 -9 /L, and platelets less than 100 x 10 -9 /L were the strongest factors associated with inferior OS ( was possible to compute the score, the prognostic index showed a comparable property (Table 4 and Figure 2B ). Moreover, the prognostic model could reliably separate the three levels of risk either for hospitalized or not hospitalized patients (log rank, p<0.001 for both), and had comparable discrimination ability in the prospective and retrospective cohorts: c- Figure 3S in the supplements ( Figure S3 ).

The most common clinical findings at presentation among hospitalized patients with lymphoma were pneumonia (80%) and fever (76%), followed by dyspnoea (62% Medications that were delivered to admitted patients, both in terms of oxygen supplementation, inotropes, antibiotics or antiviral drugs are described in detail in Table 4S supplements. Differences in the administration of drugs or ventilation according to disease severity is also listed. Overall, hydroxychloroquine was administered to 34% of admitted patients, lopinavir in 34%, remdesivir in 41%, and antibiotics in 74%. Deep-vein thrombosis prophylaxis was delivered to 71% of patients, and 6% had tocilizumab.

In the present study, we evaluated the impact of COVID19 on survival of Italian lymphoma patients. To the best of our knowledge, this is the largest series of patients reported so far, and has some unique characteristics, that may impact clinical practice: (1) it includes a large prospective cohort (n=619), (2) it has the longest follow-up to date, (3) it includes both hospitalized and not hospitalized patients. Overall, we could draw conclusions on a population with a wide age distribution, affected by lymphoid malignancies with variable disease status, and with several lymphoma histologies that were well represented. With the present study, we can conclusively say that fatality rate of hospitalized patients with lymphoma is high (33.4%), which was in line with smaller retrospective series from the literature on lymphoma patients 17, 23 , or on HM in general [12] [13] [14] [15] [16] 24 . Furthermore, we could establish for the first time the relatively low mortality rate (3.8%) of patients that were managed as outpatients. Our analysis confirmed that the demographic characteristics of the patients are of main importance in the COVID19-and-cancer scenario. Male gender and advanced age (>65 years-old) by themselves, conferred a significant higher risk of death to patients with lymphoma and COVID19, with hazard ratios in the range of 2 and 3.5, respectively. When demographic characteristics were paired by platelet and lymphocyte count, we could build an easy-to-use prognostic model that identified patients with approximately 50% probability of death in the initial 2 months after COVID19 infection (Table 4 , Figure 2 ). Our prognostic model successfully applied both to admitted and not admitted patients. The detrimental role of lymphopenia and thrombocytopenia in our model can be explained by the impaired humoral and cell-mediated response, as well as seroconversion related to lymphopenia, and to the association of thrombocytopenia to acute inflammation, when proinflammatory mediators are released, and systemic endothelial damage occurs. Of note, the reason for death was registered as a prerequisite in our database, to avoid overestimation bias in the rate of death due to comorbidities or other reasons that were not COVID-related. Indeed, 91% of the registered and computed deaths were reported as COVID-related. We acknowledge that the performance of our model was not verified in independent series, although it was validated internally ( Figure   2 ), and therefore we need to consider our findings as hypothesis generating for future external validation. Overall, these findings may assist haematologists and national health commissions in their decision-making processes regarding preventive measures and treatment in this patient population. Vaccination has been shown to be not as effective in lymphoma patients as in the normal setting, making this population more vulnerable to COVID19 [25] [26] [27] [28] . A substantial subset of vaccinated lymphoma patients may be at high risk of breakthrough COVID19 infection 28 . Adapted vaccination schedules for lymphoma patients, expecially when exposed to anti-CD20 including regimens, are urgently needed, as this highlights the need for continuous careful monitoring of this frail population.

Our work may facilitate a change in some common thinking about the impact of delivered anti-lymphoma treatment on fatality rate. We observed no differences in survival for patients on active anti-lymphoma treatment (≤6 months), as compared to all others ( Table   2 ). This observation confirms other observations on lymphoma patients 14, 17, 23 , but differs from what generally reported in solid cancer patients, where active treatment has been associated with increased risk of death 29,30 , although not uniformly 13, 31 . Anti-CD20

containing therapy, as already observed by others 16 , did not impact the short-term outcome, as was the case of the number of previous anti-lymphoma lines of therapy.

However, this aspect will need to be clarified further, in view of the recently described strong association between anti-CD20 containing therapy and impaired immune response to vaccination. [25] [26] [27] [28] The use of bendamustine was not statistically associated with impaired survival in our series, but larger samples will be needed to confirm this observation.

Instead, based on our findings, withholding specific treatments does not seem to be justified, since the presence of active disease was uniformly associated with higher risk of death in ours and other series 17, 18 .

Our analysis showed that an initial lymphoma diagnosis of 3 or more years prior to COVID19 infection was significantly associated with better clinical behaviour and inferior fatality rate. This observation, which to our knowledge, has not been previously reported, may facilitate the screening of patients that may be candidate to early vaccination strategies (Figure 3 ).

In the COVID19 literature only few retrospective series specifically describing patients with lymphoma have been published so far 16, 17 . We observed that patients with cHL had a lower rate of admission to the hospital, and the lowest mortality rate among all subtypes.

This was consistent with several other reports, with the limit of the low number of cHL patients included in the other series 16 However, our model was predictive in each subgroup of the prognostic indexes related to lymphoma histotype both in aggressive and indolent histologies(IPI, FLIPI, MIPI, Figure   S3 ).

All patients that were not admitted to the hospital (n=388) were enrolled prospectively by centers. This makes this cohort informative regarding the ability of our model to predict survival of not hospitalized patients. Indeed, the vast majority of lymphoma patients included in previous reports were admitted to the hospital (85% and 100% in the Spanish and French reports, respectively 16, 17 ). The signs and symptoms related to COVID19 infection in this population were obviously milder than hospitalized patients: fever, pneumonia, or cough were registered in 53%, 10%, and 36% of not admitted patients, respectively, as compared to 76%, 80%, and 53% for hospitalized patients. Analysing the effectiveness of the various COVID19 treatments to improve final outcome represents a crucial objective of scientific research in the COVID19 era, but it was outside the aims of the present report. Furthermore, longitudinal observation of our patients may inform us about the impact of long-COVID19, and how long-lasting signs or symptoms may have affected the subsequent treatment of underlying lymphoma. This aspect warrants further investigations.

In conclusion we have reported a high mortality rate in patients with lymphoma and COVID19, which can be easily predicted both in hospitalized and not hospitalized patients by demographics or haematological ready-to-use variables. Our study, which was largely based on a prospectively enrolled cohort, may represent the basis for future comparison in such an intriguing field of modern translational medicine.

For data sharing, contact the corresponding author: carlo.visco@univr.it.

Authors wish to thank all the patients and families who were included to this study, as all the health workers that took care of our patients in Italy. This study received no specific financial support. We thank the charity Associazione italiana contro le leucemie, linfomi e mieloma-Verona Onlus. We thank Emilia Elizbieta Florea for the precious administrative assistance. ** Ratio: ratio between the z-score for any factor divided by minimum z-score observed (platelets, considered as reference). The weights were obtained rounding the ratio. Score: sum of weights. ***Internal validation performed after 1000 bootstrap resamples. Time lapse between lymphoma diagnosis and COVID19 (months) Figure 3 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

The first two cases of 2019-nCoV in Italy: Where they come from

Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper

COVID-19: consider cytokine storm syndromes and immunosuppression

A 63-year-old woman with a history of nonhodgkin lymphoma with persistent sars-cov-2 infection who was seronegative and treated with convalescent plasma

Characteristics of and Important Lessons from the

COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention

Presenting Characteristics, Comorbidities, and Outcomes among 5700 Patients Hospitalized with COVID-19 in the New York City Area

Age-specific mortality and immunity patterns of SARS-CoV-2

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Case fatality rate of cancer patients with COVID-19 in a New York Hospital system

Risk factors and outcome of COVID-19 in patients with hematological malignancies

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study

Determinants of outcome in Covid-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study

COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Regression Models and Life-Tables

A strategy for modelling the effect of a continuous covariate in medicine and epidemiology -Royston -2000 -Statistics in Medicine -Wiley Online Library

Partial Residuals for The Proportional Hazards Regression Model

Under COVID of the night

Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies

Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies